dogs, intracoronary doses of CV-1674, adenosine (ADS) and 2-CI-ADS for doubling coronary flow were estimated as 5.0, 2.0 and 0.4 fig/dog, and i.v. doses 31, 71 and 2.5 jig/kg, respectively. ADS and 2-Cl-ADS decreased, while CV-1 674 increased LV dp/dt. Intravenous infusion (30 min) of CV-1674 (10 rig/kg per min) and ADS (700 ,g/kg per min) decreased coronary resistance to approximately the same extent. Decreases in blood pressure, total peripheral resistance and myocardial O2 consumption with ADS were more prominent than those with CV-1674. ADS produced a marked bradycardia that was not evident with CV-1674. Neither agent had a significant influence on myocardial efficiency. In guinea pig atria, ADS and 2-Cl-ADS exerted negative effects while those with CV-1674 were positive inotropic and chronotropic. In cats, intraduodenal ADS (10 mg/kg) produced no effects on cardiohemodynamic parameters.
uptake by red blood cells and tissues such as in the lung, and its breakdown to inosine by adenosine deaminase (3, 4) .
Attempts have been made to find derivatives more resistant to the inactivating mechanisms and more selective for the coronary system. Among these derivatives, 2-chloroadenosine (2-C1-ADS) has been found to be more potent and longer-acting as a coronary vasodilator, but has a stronger cardiac de pressant action than ADS (5, 6) . Recently, Marumoto, et al. which were more selective than ADS for the coronary vasculature. Among these derivatives, CV-1 674, the chemical structure of which is shown in Fig. 1 , appeared to be the most inter esting. The present paper describes effects of the agent on coronary hemodynamics and myocardial energetics in anesthetized animals and the cardiac actions in isolated pre parations as compared with those of ADS and 2-Cl-ADS.
MATERIALS AND METHODS

Hemodynaniic and myocardial energetic studies in dogs
Mongrel dogs of either sex weighing 7.0 to 12.0 kg for coronary hemodynamics and 15.0 to 35.0 kg for myocardial energetic studies were anesthetized with sodium pentobarbital (30 mg/kg, i.v.). In experiments of coronary hemodynamics, the animals were artificially respired with room air, the chest was opened by an incision at the 5th intercostal space and the heart hammocked in the pericardial cradle. After heparinization (500 units/kg, i.v.), the circumflex branch of the left coronary artery was ligated near the bifurcation, and cannulated antegradely with polyethylene tubing. The blood supplying the circumflex area was led from the left carotid artery via an extracorporeal circuit in which a cannulating-type flow probe of an electromagnetic flowmeter (EMF) (Nihon Kohden, MF-2) was interposed to measure coronary blood flow (CBF). The left femoral artery was cannulated for measure ment of systemic blood pressure (BP) with an electromanometer (Nihon Kohden, MP-4T), and the ipsilateral femoral vein for i.v. injection of agents. Polyethylene tubing was inserted into the left ventricular cavity through the left auricle to measure the left ventricular pressure (LVP) and its dp/dt (LV dp/dt). An intracoronary injection of agents was made through a T-glass tube interposed in the extracorporeal circuit.
In experiments of hemodynamics and myocardial energetics, the animal was artificially respired and the right chest opened by an incision at the 4th intercostal space. A poly ethylene Morawitz-type cannula was inserted into the coronary sinus through the right auricle. Coronary sinus outflow was led into the right external jugular vein via an extra corporeal circuit, in which a cannulating-type EMF probe was interposed to measure CBF.
A non-cannulating-type flow probe of an EMF (Nihon Kohden, MF-46) was set around the ascending aorta to measure aortic blood flow (AF). After these instruments were secured in place, the chest was closed under a negative intrapleural pressure of about 50 cm H2O, experiments were conducted under spontaneous respiration. The right common carotid artery was cannulated for measurement of BP. Heart rate (HR) was registered with a pulse rate tachometer (Nihon Konden, RT-2) triggered by BP pulses. These hemodynamic parameters were recorded on an ink-writing polygraph recorder (Nihon Kohden, RM-150). Mean CBF was registered through an electronically integrated circuit, and mean AF was calculated planimetrically from 3 cardiac cycles recorded at a chart speed of 5 cm/sec. used by approximately estimating coronary sinus outflow as 70'0 of total coronary blood flow (9).
The results were statistically treated according to a multiple comparison procedure. 
Experiments on isolated guinea pig atria
Male Hartley guinea pigs weighing 250 to 400 g were sacrificed by a blow on the head, and the heart was immediately removed. Atria dissected from ventricles were separated into left and right atrium, and both preparations were suspended in a same bath containing 20 ml of oxygenated Krebs-Henseleit's solution maintained at 30°C . A resting tension of 0.5 g was applied. Left atrium was driven by electrical stimuli (5V, I cosec) at a constant rate of 60 beats/min. The developed tension was isometrically recorded via a strain gauge transducer (Nihon Kohden, SB-IT), and the beating rate of spontaneously beating right atrium was registered with a pulse rate tachometer (Nihon Kohden, RT-2) triggered by the developed tension. After an equilibration period (40 to 60 min), test agents were added to the bath, and the effects were observed for 10 min thereafter.
Agents used were ADS, CV-1674, 2-Cl-ADS and aminophylline (APL) (Fujisawa, Co.).
ADS and its derivatives were synthetized by Marumoto et al. (7). ADS and 2-Cl-ADS
were dissolved in 0.9',,') saline solution. CV-1674 was dissolved in less than 10% poly ethylene-glycol-400 (PEG) Solution.
RESULTS
Coronary vasodilator activities of CV-1674 administered via different routes a) Intracoronary injection in dogs
Intracoronary (i.e.) bolus injections of 1.0 to 100 pig/dog of CV-1674 produced a dose dependent increase in CBF ( Fig. 2A) , which reached a peak within 30 sec and decayed Bolus injections of 0.3 to 10.0 ;cg/dog of ADS also caused a dose-dependent increase in CBF ( Fig. 2A) , which was more rapid in onset and much shorter in duration than that of CV-1674, i.e., the increase in CBF reached a peak in about 10 sec and almost completely subsided within 30 to 60 sec after injection. 2-C1-ADS was the most potent in increasing CBF among three analogues ( Fig. 2A ). The highest dose tested of 2-Cl-ADS, elicited systemic hypotension and bradycardia, whereas CV-1674 and ADS produced little changes in BP and HR even at the highest dose tested.
The doses of CV-1674, ADS and 2-Cl-ADS required to double CBF were estimated as A: CV-1674, B: 2-chloroadenosine. SP, DP and MP: systolic, diastolic and mean blood pressure, respectively, LVP and max. LVdp/dt: left ventricular pressure and its dp/dt, HR: heart rate, CBF: coronary blood flow. n: number of experiments a plateau with 100 pg/kg, but the longer was the duration with the higher dose of the agent.
CV-1674 slightly decreased LVP with a moderate increase in max. LVdp/dt in higher doses (Fig. 3A) . The agent elicited a transient, slight increase followed by a slight decrease in HR (Fig. 3A) .
Although ADS elicited no herodynamic alteration with a dose of 10 dig/kg, i.v., doses ranging from 30 to 250 /ig/kg produced an immediate and dose-dependent increase in CBF (Fig. 2B) and decreases in BP, LVP and its dp/dt. These effects of ADS were short-lived and disappeared within a few min after injection. 2-Cl-ADS also produced a dose-dependent increase in coronary blood flow with doses over 0.3 1g/kg, and the maximum effect was reached with 3 /Lg/kg (Fig. 2B) . The agent, however, significantly depressed all hemodynarnic parameters, except for a slight increase in max. LVdp/dt early after administration of lower doses, and a less increase in CBF due to systemic hypotension was observed with 10 /Ig/kg instead of pentobarbitalized dogs, since maintenance of a stable cardiohernodynamic con dition required for evaluation of a slow-developing, long-lasting effect of test agents admin istered intraduodenally was found to be easier in the former preparations than in the latter.
Intraduodenal administration of 250 and 500 ,,cg/kg of CV-1674 increased MBF in a dose-dependent manner, with concomitant decreases in BP and HR with the higher dose.
The increase in MBF reached a maximum 20 to 30 min after the administration and lasted for more than 120 min (Fig. 4A) . On the other hand, i.d. administration of 2-Cl-ADS increased the MBF only in the highest dose (500 ; eg/kg, i.d.) tested. However, the depressant effects of 2-Cl-ADS on BP and HR were more marked than those of CV-1674 (Fig. 4B) .
ADS produced no effect on MBF, BP and HR with an i.d. dose of 10 mg/kg.
With this route of administration, CV-1674 was found to be the most potent among the three analogues.
inn tropic and clnronotropic actions in isolated guinea pig atria Effects of CV-1674 on isolated guinea pig atria differed from those of ADS and 2-Cl ADS. In isolated, electrically driven left atria CV-1674 produced a slight positive inotropic action with rather high doses of 10-5-10-1 g/ml, as shown in Fig. 5 . The inotropic action appeared gradually after application of the agent, and attained the maximum at the end of a 10-min incubation period. Beating rate in spontaneously beating right atria slightly increased on application of the agent, although the effect did not appear to be dose-dependent (Fig. 5 ). In these preparations 3 ;: 10-1 g/ml did not affect contractile force nor beating rate. In contrast, ADS (10-1-10-6 g/ml) and 2-Cl-ADS (10-8-10_7 g/ml) decreased contractile force of electrically driven left atria and beating rate of spontaneously beating right atria in a dose-dependent manner (Fig. 5) . The effects of both compounds appeared immediately after application, and attained the maximum within a few min. The effects of ADS decayed with time, while those of 2-Cl-ADS were maintained thereafter. 
Interaction u ith aminophylline in cats
The effect of pretreatment with APL on the hypotensive action of CV-1674
and ADS was studied in cats, since the cardiovascular actions of ADS are known to be inhibited by APL (11, 12) .
The pretreatment with 5 mg/kg i.v.
of APL 10 min prior to challenging with CV-1674 (100 ,'ig!kg) or ADS (500 ,' gjkg) markedly inhibited the hypotensive action of both agents, and the negative chrono tropic action of ADS (Fig. 6 ).
Cardiohcnrodynan:is and myocardial encr g ctics
In this series of experiments, test agents were infused intravenously to determine the effects in a steady state.
Ten and 700 /eg/kg per min for 30 min of CV-1674 and ADS, respectively, were used as test doses, since it was found in preliminary experiments that these doses decreased CR to a comparable extent.
Of all the cardiohemodynamic parameters changed with CV-1674 administration, the increase in CBF was the most prominent, the flow having increased from 49.7-8. (Table I A) . On the other hand, changes in CBF after ADS differed in degree and direction from one animal to another probably due to prominent cardiohemodynamic depressions, although CR decreased in all preparations during infusion of ADS (Table I B) . The flow rate increased in 3 out of 5 experiments, and decreased slightly in 2.
Either agent significantly lowered BP, although ADS exerted a more prominent hy potensive effect than CV-1674 (Table 1) . Mean AF was not significantly affected by either agent, while SV increased after ADS. TPR significantly decreased after either agent (Table   1) . ADS produced prominent bradycardia, from 158--' 10 beats/min immediately before to 127-16 (p-,;0.01) and 130_ _6 (p-__0.05) beats/min 5 and 30 min after administration, respectively. CV-1674 slightly increased HR in the early stages and decreased it at the end of infusion (Table 1) .
SW and CW slightly decreased after either agent, and the decrease in CW were sta tistically significant at the end of infusion ( cantly at the end of infusion of CV-1674, but the decrease recovered after the cessation of infusion (Table IA) . Eff. was not affected by the agent (Table ] A). ADS significantly decreased MVO2 during the period of infusion (Table I B) . The decrease was more prominent than that in CW, and Eff. slightly increased, although such was not statistically significant (Table 113) . In all series of experiments, the solvent (PEG) in concentrations less than 10%, used to dissolve CV-1674, did not significantly affect the parameters in question.
DISCUSSION
A newly synthetized adenosine derivative, CV-1674, shows interesting pharmacological features as compared with ADS and 2-CI-ADS in the following respects: i) a difference in relative potencies to increase coronary blood flow depending on different routes of admin istration, and 2) a less degree of depression in cardiohemodynamics.
In dogs, the coronary vasodilator potency of CV-1674 was less than half that of ADS with i.c. injection ( Fig. 2A) . With Lv. administration, especially continuous infusion, however, CV-1674 had a higher potency than ADS, although CV-1674 was much less potent than 2-Cl-ADS even with this route of administration ( indicating that CV-1674 and 2-C1-ADS are more resistant to inactivating mechanisms than ADS. Furthermore, CV-1674 was found to be more potent than 2-Cl-ADS with i.d. admin istration in cats (Fig. 4) , suggesting that CV-1674 is relatively well absorbed from the intestinal tract. ADS was practically inactive in this respect.
ADS and 2-C1-ADS are known to exert cardiohemodynamic depressions in addition to coronary vasodilation (2) . In the present study, prominent cardiohemodynamic effects of ADS were bradycardia in dogs (Table 113 ) and negative inotropic and chronotropic actions in isolated guinea pig atria ( Table   IA) , increased LVdp/dt in dogs (Fig. 3A) , and caused slightly positive inotropic and chrono tropic actions in isolated guinea pig atria (Fig. 5) . The results clearly indicates that CV-1674 has a specificity for the coronary bed. In cats, a depressor effect of CV-1674 and ADS was inhibited by pretreatment with APL (Fig. 6 ). Considering the similarity of the structure of CV-1674 and ADS, it is suggested that CV-1674 acts on the same vascular receptors as ADS. ADS apparently affects MVO2 in a various manner depending on preparations used. (Table 1) . Raberger et al. (16) and Schauman et al. (19) proposed that ADS produced a decrease in MVO2 via an action on myocardial substrate metabolism. Lammerant et al. (17) suggested that the decrease in MVO2 might be due to a redistribution of blood flow from a high 02 extracting region (subendocardiurn) to a low 02 extracting one (subepicardium) of the myocardium. It has also been argued that MVO2 is closely related to the product of the systolic blood pressure and heart rate (20) . Thus, it seems likely that the decrease in MVO2 after ADS and CV-1674 as noted in the present study may reflect changes in cardio hemodynamics, since ADS, which elicited prominent hypotension and bradycardia, de creased MVO2 more prominently than CV-1674, which elicited only a lesser degree of hypotension (Table 1) . Both CV-1674 and ADS decreased CW as the result of a decrease in afterload of aortic blood pressure, however, myocardial efficiency remained unaffected because of a concomitant decrease in MVO2 (Table 1 ).
In conclusion, CV-1674 induces selective coronary vasodilation with less depression on card iohemodynamics, and is relatively well absorbed from the intestinal tract. Furthermore, unlike ADS and 2-Cl-ADS, CV-1674 produced slightly positive inotropic and chronotropic actions on isolated guinea pig atria. The pharmacological profile of the compound, thus, differs from that of ADS and 2-Cl-ADS.
